EUVIMEDEUVIMED entdecken
Crossref

The proportion of tumour stroma predicts response to treatment of immune checkpoint inhibitor in combination with chemotherapy in patients with stage IIIB−IV non‐small cell lung cancer

Lina Yi, Yingmei Wen, Mengxia Xiao, Jingping Yuan iD, Xiaokang Ke, Xiuyun Zhang, Liaqat Khan, Qibin Song, Yi Yao iD

Histopathology · 2024

DOI: 10.1111/his.15202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Lina Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province of China, Beijing Medical and Health Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Immunotherapy has brought a new era to cancer treatment, yet we lack dependable predictors for its effectiveness. This study explores the predictive significance of intratumour stroma proportion (iTSP) for treatment success and prognosis in non‐small cell lung cancer (NSCLC) patients undergoing treatment with immune check‐point inhibitors (ICIs) together with chemotherapy. Methods and results We retrospectively collected data from patients with unresectable stage IIIB−IV NSCLC who were treated with first‐line ICIs and chemotherapy. Each patient received a confirmed pathological diagnosis, and the pathologist evaluated the iTSP on haematoxylin and eosin (H&E)‐stained sections of diagnostic tissue slides. Among the 102 H&E‐stained biopsy samples, 61 (59.8%) were categorised as stroma‐L (less than 50% iTSP), while 41 (40.2%) were classified as stroma‐H (more than 50% iTSP). We observed that the stroma‐L group exhibited a significantly better objective response rate (ORR) (72.1 versus 51.2%, P = 0.031) and deeper response depth (DpR) (−50.49 ± 28.79% versus −35.83 ± 29.91%, P = 0.015) compared to the stroma‐H group. Furthermore, the stroma‐L group showed longer median progression‐free survival (PFS) (9.6 versus 6.0 months, P = 0.011) and overall survival (OS) (24.0 versus 12.2 months, P = 0.001) compared to the stroma‐H group. Multivariate Cox proportional hazards regression analysis indicated that iTSP was a highly significant prognostic factor for both PFS [hazard ratio (HR) = 1.713; P = 0.030] and OS (HR = 2.225; P = 0.003).

Conclusion

Our findings indicate that a lower iTSP corresponds to improved clinical outcomes and greater DpR in individuals with stage IIIB−IV NSCLC treated with first‐line ICIs and chemotherapy. The iTSP could potentially serve as a predictive biomarker for ICIs therapy response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesPrognosisAdultAntineoplastic Combined Chemotherapy ProtocolsNeoplasm StagingAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

biomarkerchemotherapyimmune checkpoint inhibitorintratumour stroma proportion (iTSP)non‐small cell lung cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
  • Department of Oncology, Yichun People's Hospital, Yichun, China.
  • Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China.
  • Research Center, Benazir Bhutto Hospital of Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Hubei Provincial Research Center for Precision Medicine of Cancer, Wuhan, China.

ORCID-Profile: Jingping Yuan, Yi Yao

Förderung

  • Natural Science Foundation of Hubei Province of China
  • Beijing Medical and Health Foundation

Zitieren

APA

Yi, L., Wen, Y., Xiao, M., Yuan, J., Ke, X., Zhang, X., Khan, L., Song, Q., & Yao, Y. (2024). The proportion of tumour stroma predicts response to treatment of immune checkpoint inhibitor in combination with chemotherapy in patients with stage IIIB−IV non‐small cell lung cancer. Histopathology. https://doi.org/10.1111/his.15202

Vancouver

Yi L, Wen Y, Xiao M, Yuan J, Ke X, Zhang X, et al. The proportion of tumour stroma predicts response to treatment of immune checkpoint inhibitor in combination with chemotherapy in patients with stage IIIB−IV non‐small cell lung cancer. Histopathology. 2024. doi:10.1111/his.15202

BibTeX
@article{Yi2024,
  author = {Yi, Lina and Wen, Yingmei and Xiao, Mengxia and Yuan, Jingping and Ke, Xiaokang and Zhang, Xiuyun and Khan, Liaqat and Song, Qibin and Yao, Yi},
  title = {The proportion of tumour stroma predicts response to treatment of immune checkpoint inhibitor in combination with chemotherapy in patients with stage IIIB−IV non‐small cell lung cancer},
  journal = {Histopathology},
  year = {2024},
  doi = {10.1111/his.15202}
}
Kostenlos starten →